Combined therapy with cyclophosphamide and DNA preparation inhibits the tumor growth in mice

Genetic Vaccines and Therapy

Volumn 7, Issue , 2009, Pages

  Alyamkina, Ekaterina A ^a   Dolgova, Evgenia V ^a   Likhacheva, Anastasia S ^b   Rogachev, Vladimir A ^b   Sebeleva, Tamara E ^b   Nikolin, Valeriy P ^b   Popova, Nelly A ^a,b   Orishchenko, Konstantin E ^b   Strunkin, Dmitriy N ^c   Chernykh, Elena R ^d   Zagrebelniy, Stanislav N ^a   Bogachev, Sergei S ^b   Shurdov, Mikhail A ^e  

^a NOVOSIBIRSK STATE UNIVERSITY   (Russian Federation)

^b INSTITUTE OF CYTOLOGY AND GENETICS   (Russian Federation)

^c Municipal Hospital   (Russian Federation)

^d INSTITUTE OF CLINICAL IMMUNOLOGY   (Russian Federation)

^e LLC Panagen ^*  (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DNA FRAGMENT; DOUBLE STRANDED DNA; GENOMIC DNA; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GENE THERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; CANCER TRANSPLANTATION; CARCINOMA; CBA MOUSE; CONTROLLED STUDY; IMMUNIZATION; MONOTHERAPY; MOUSE; NONHUMAN; SURVIVAL RATE; TISSUE HOMOGENATE; TUMOR XENOGRAFT;

MUS;

EID: 69549129482     PISSN: None     EISSN: 14790556     Source Type: Journal    
DOI: 10.1186/1479-0556-7-12     Document Type: Article

References (37)

1. Wang H Rayburn ER Wang W Kandimalla ER Agrawal S Zhang R Chemotherapy and chemosensitization of non-small cell lung cancer with a novel immunomodulatory oligonucleotide targeting Toll-like receptor 9 Mol Cancer Ther 2006, 5:1585-1592. 10.1158/1535-7163.MCT-06-0094 16818518
2. Olishevsky SV Kozak VV Yanish YuV Rybalko SL Shliakhovenko VA Immunostimulatory CpG DNA: Prospects for clinical use in oncology Oncologia 2006, 8:209-217. In Russian
3. Ishii KJ Akira S Innate immune recognition of, and regulation by, DNA Trends Immunol 2006, 27:525-532. 10.1016/j.it.2006.09.002 16979939
4. Krieg AM Development of TLR9 agonists for cancer therapy J Clin Invest 2007, 117:1184-1194. 10.1172/JCI31414 1857270 17476348
5. Medzhitov R Recognition of microorganisms and activation of the immune response Nature 2007, 449:819-826. 10.1038/nature06246 17943118
6. Rakoff-Naum S Medzhitov R Role of Toll-like receptors in tissue repair and carcinogenesis Biokhimia 2008, 73:690-698.
7. Hartmann G Krieg AM CpG DNA and LPS induce distinct patterns of activation in human monocytes Gene Ther 1999, 6:893-903. 10.1038/ sj.gt.3300880 10505115
8. Pulendran B Variegation of the immune response with dendritic cells and pathogen recognition receptors J Immunol 2005, 174:2457-2465. 15728447
9. Otto F Schmid P Mackensen A Wehr U Seiz A Braun M Galanos C Mertelsmann R Engelhardt R Phase II trial of intravenous endotoxin in patients with colorectal and non-small cell lung cancer Eur J Cancer 1996, 32A:1712-1718. 10.1016/0959-8049(96)00186-4 8983279
10. Liu YJ IPC: Professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors Annu Rev Immunol 2005, 23:275-306. 10.1146/annurev.immunol.23.021704.115633 15771572
11. Kawai T Akira S Innate immune recognition of viral infection Nat Immunol 2006, 7:131-137. 10.1038/ni1303 16424890
12. Zou W Regulatory T cells, tumour immunity and immunotherapy Nat Rev Immunol 2006, 6:295-307. 10.1038/nri1806 16557261
13. Carson WE 3rd Shapiro CL Crespin TR Thornton LM Andersen BL Cellular immunity in breast cancer patients completing taxane treatment Clin Cancer Res 2004, 10:3401-3409. 10.1158/1078-0432.CCR-1016-03 15161695
14. Beyer M Kochanek M Darabi K Popov A Jensen M Endl E Knolle PA Thomas RK von Bergwelt-Baildon M Debey S Hallek M Schultze JL Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine Blood 2005, 106:2018-2025. 10.1182/blood-2005-02-0642 15914560
15. Correale P Cusi MG Tsang KY Del Vecchio MT Marsili S Placa ML Intrivici C Aquino A Micheli L Nencini C Ferrari F Giorgi G Bonmassar E Francini G Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer patients J Clin Oncol 2005, 23:8950-8958. 10.1200/JCO.2005.12.147 16061910
16. Emens LA Jaffee EM Leveraging the activity of tumor vaccines with cytotoxic chemotherapy Cancer Res 2005, 65:8059-8064. 10.1158/ 0008-5472.CAN-05-1797 16166275
17. Ercolini AM Ladle BH Manning EA Pfannenstiel LW Armstrong TD Machiels JP Bieler JG Emens LA Reilly RT Jaffee EM Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response J Exp Med 2005, 201:1591-1602. 10.1084/jem.20042167 2212915 15883172
18. Ghiringhelli F Larmonier N Schmitt E Parcellier A Cathelin D Garrido C Chauffert B Solary E Bonnotte B Martin F CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative Eur J Immunol 2004, 34:336-344. 10.1002/eji.200324181 14768038
19. Lake RA Robinson BW Immunotherapy and chemotherapy - a practical partnership Nat Rev Cancer 2005, 5:397-405. 10.1038/nrc1613 15864281
20. Lutsiak ME Semnani RT De Pascalis R Kashmiri SV Schlom J Sabzevari H Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide Blood 2005, 105:2862-2868. 10.1182/blood-2004-06-2410 15591121
21. Machiels JP Reilly RT Emens LA Ercolini AM Lei RY Weintraub D Okoye FI Jaffee EM Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice Cancer Res 2001, 61:3689-3697. 11325840
22. Chu Y Wang LX Yang G Ross HJ Urba WJ Prell R Jooss K Xiong S Hu HM Efficacy of GM-CSF-producing tumor vaccine after docetaxel chemotherapy in mice bearing established Lewis lung carcinoma J Immunother 2006, 29:367-380. 10.1097/01.cji.0000199198.43587.ba 16799332
23. Motoyoshi Y Kaminoda K Saitoh O Hamasaki K Nakao K Ishii N Nagayama Y Eguchi K Different mechanisms for anti-tumor effects of low- and high-dose cyclophosphamide Oncol Rep 2006, 16:141-146. 16786137
24. Taieb J Chaput N Schartz N Roux S Novault S Ménard C Ghiringhelli F Terme M Carpentier AF Darrasse-Jèze G Lemonnier F Zitvogel L Chemoimmunotherapy of tumors: Cyclophosphamide synergizes with exosome based vaccines J Immunol 2006, 176:2722-2729. 16493027
25. Ikezawa Y Nakazawa M Tamura C Takahashi K Minami M Ikezawa Z Cyclophosphamide decreases the number, percentage and the function of CD25+ CD4+ regulatory T cells, which suppress induction of contact hypersensitivity J Dermatol Sci 2005, 39:105-112. 10.1016/ j.jdermsci.2005.02.002 15899580
26. Nikolin VP Popova NA Sebeleva TE Strunkin DN Rogachev VA Semenov DV Bogachev SS Yakubov LA Shurdov MA Effect of exogenous DNA injection on leukopoietic repair and antitumor action of cyclophosphamide Vopr Onkol 2006, 52:336-340. In Russian 17191708
27. Likhacheva AS Nikolin VP Popova NA Dubatolova TD Strunkin DN Rogachev VA Sebeleva TE Erofeev IS Bogachev SS Yakubov LA Shurdov MA Integration of human DNA fragments into the cell genomes of certain tissues from adult mice treated with cytostatic cyclophosphamide in combination with human DNA Gene Ther Mol Biol 2007, 11:185-202.
28. North RJ Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells J Exp Med 1982, 155:1063-1074. 10.1084/jem.155.4.1063 2186638 6460831
29. Curiel TJ Coukos G Zou L Alvarez X Cheng P Mottram P Evdemon-Hogan M Conejo-Garcia JR Zhang L Burow M Zhu Y Wei S Kryczek I Daniel B Gordon A Myers L Lackner A Disis ML Knutson KL Chen L Zou W Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival Nat Med 2004, 10:942-949. 10.1038/nm1093 15322536
30. Jordan JT Sun W Hussain SF DeAngulo G Prabhu SS Heimberger AB Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy Cancer Immunol Immunother 2008, 57:123-131. 10.1007/s00262-007-0336-x 17522861
31. Polak L Turk JL Reversal of immunological tolerance by cyclophosphamide through inhibition of suppressor cell activity Nature 1974, 249:654-656. 10.1038/249654a0 4275846
32. Berd D Mastrangelo MJ Effect of low dose cyclophosphamide on the immune system of cancer patients: Depletion of CD4+, 2H4+ suppressor-inducer T-cells Cancer Res 1988, 48:1671-1675. 2830969
33. Weigel BJ Rodeberg DA Krieg AM Blazar BR CpG oligodeoxynucleotides potentiate the antitumor effects of chemotherapy or tumor resection in an orthotopic murine model of rhabdomyosarcoma Clin Cancer Res 2003, 9:3105-3114. 12912962
34. Obeid M Tesniere A Ghiringhelli F Fimia GM Apetoh L Perfettini JL Castedo M Mignot G Panaretakis T Casares N Métivier D Larochette N van Endert P Ciccosanti F Piacentini M Zitvogel L Kroemer G Calreticulin exposure dictates the immunogenicity of cancer cell death Nat Med 2007, 13:54-61. 10.1038/nm1523 17187072
35. Obeid M Panaretakis T Tesniere A Joza N Tufi R Apetoh L Ghiringhelli F Zitvogel L Kroemer G Leveraging the immune system during chemotherapy: moving calreticulin to the cell surface converts apoptotic death from "silent" to immunogenic Cancer Res 2007, 67:7941-7944. 10.1158/ 0008-5472.CAN-07-1622 17804698
36. Pratesi G Petrangolini G Tortoreto M Addis A Belluco S Rossini A Selleri S Rumio C Menard S Balsari A Therapeutic synergism of gemcitabine and CpG-oligodeoxynucleotides in an orthotopic human pancreatic carcinoma xenograft Cancer Res 2005, 65:6388-6393. 10.1158/0008-5472.CAN-05-0602 16024642
37. Wang XS Sheng Z Ruan YB Guang Y Yang ML CpG oligodeoxynucleotides inhibit tumor growth and reverse the immunosuppression caused by the therapy with 5-fluorouracil in murine hepatoma World J Gastroenterol 2005, 1: 1220-1224. 15754409